- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Science
- Onco-Metabolism Platform
- Therapeutic Areas
- Publications
- Programs
- Pipeline
- Glutaminase Inhibitor CB‑839
- Arginase Inhibitor INCB001158
- Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Media & Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
Science
Publications and Presentations
Check out our publications and poster presentations.
December 2017
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.Journal for ImmunoTherapy of Cancer
December 2017
November 2017
CX-839-004: A phase 1/2 study of CB-839, a first-in-class glutaminase inhibitor, combined with nivolumab in patients with advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer-Oral Presentation CX-839-004: A phase 1/2 study of CB-839, a first-in-class glutaminase inhibitor, combined with nivolumab in patients with advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung CancerSociety for Immunotherapy of Cancer
June 2017
March 2017
CB-839, a Selective Glutaminase Inhibitor, has Anti-Tumor Activity in Renal Cell Carcinoma and Synergizes with Cabozantinib and EverolimusKeystone Symposia on Tumor Metabolism
Our Pipeline
We are focused on solid tumors for
which new treatments are urgently needed.